New molecular diagnosis and screening methods for colorectal cancer using fecal protein, DNA and RNA

References

• World Health Organization. The Global Burden of Disease: 2004 Update. WHO Press, Geneva, Switzerland 2008.
   Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA. Cancer J. Clin. 63(1), 11–30 (2013).
   PubMed Web of Science ®Google Scholar
• Matsuda T, Marugame T, Kamo K et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J. Clin. Oncol. 42(2), 139–147 (2012).
   PubMed Web of Science ®Google Scholar
• Matsuda T, Ajiki W, Marugame T et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn. J. Clin. Oncol. 41(1), 40–51 (2011).
   PubMed Web of Science ®Google Scholar
• Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA. Cancer J. Clin. 61(1), 8–30 (2011).
   PubMed Web of Science ®Google Scholar
• Cancer Statistics in Japan 2012. Foundation for Promotion of Cancer Research, Tokyo, Japan 2012.
   Google Scholar
• Yamao T, Matsumura Y, Shimada Y et al. Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 114(6), 1196–1205 (1998).
   PubMedGoogle Scholar
• Sidransky D, Tokino T, Hamilton SR et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256(5053), 102–105 (1992).
   PubMed Web of Science ®Google Scholar
• Matsushita H, Matsumura Y, Moriya Y et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 129(6), 1918–1927 (2005).
   PubMed Web of Science ®Google Scholar
• Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N. Engl. J. Med. 328(19), 1365–1371 (1993).
   PubMed Web of Science ®Google Scholar
• Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348(9040), 1472–1477 (1996).
   PubMed Web of Science ®Google Scholar
• Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348(9040), 1467–1471 (1996).
   PubMed Web of Science ®Google Scholar
• Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J. Natl Cancer Inst. 91(5), 434–437 (1999).
   PubMed Web of Science ®Google Scholar
• Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 50(6), 840–844 (2002).
   PubMed Web of Science ®Google Scholar
• Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 50(1), 29–32 (2002).
   PubMed Web of Science ®Google Scholar
• van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135(1), 82–90 (2008).
   PubMed Web of Science ®Google Scholar
• Hol L, Wilschut JA, van Ballegooijen M et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br. J. Cancer 100(7), 1103–1110 (2009).
   PubMed Web of Science ®Google Scholar
• Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 59(1), 62–68 (2010).
   PubMed Web of Science ®Google Scholar
• Shuhaibar M, Walsh C, Lindsay F et al. A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers. Ir. J. Med. Sci. 180(1), 103–108 (2011).
   PubMedGoogle Scholar
• Parra-Blanco A, Gimeno-Garcia AZ, Quintero E et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J. Gastroenterol. 45(7), 703–712 (2010).
   PubMed Web of Science ®Google Scholar
• Faivre J, Dancourt V, Denis B et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur. J. Cancer 48(16), 2969–2976 (2012).
   PubMedGoogle Scholar
• Raginel T, Puvinel J, Ferrand O et al. A Population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. Gastroenterology 144(5), 918–925 (2013).
   PubMedGoogle Scholar
• Lieberman DA, Weiss DG; Veterans Affairs Cooperative Study Group. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N. Engl. J. Med. 345(8), 555–560 (2001).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Chan FK, Leung WK et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 124(3), 608–614 (2003).
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351(26), 2704–2714 (2004).
   PubMed Web of Science ®Google Scholar
• Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129(2), 422–428 (2005).
   PubMed Web of Science ®Google Scholar
• Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann. Intern. Med. 150(3), 162–169 (2009).
   PubMed Web of Science ®Google Scholar
• Park DI, Ryu S, Kim YH et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am. J. Gastroenterol. 105(9), 2017–2025 (2010).
   PubMed Web of Science ®Google Scholar
• Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int. J. Colorectal Dis. 27(12), 1657–1664 (2012).
   PubMed Web of Science ®Google Scholar
• Chen JG, Cai J, Wu HL et al. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test. World J. Gastroenterol. 18(21), 2682–2688 (2012).
   PubMed Web of Science ®Google Scholar
• Kronborg O, Ugstad M, Fuglerud P et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46(6), 795–800 (2000).
   PubMedGoogle Scholar
• Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49(3), 402–408 (2001).
   PubMed Web of Science ®Google Scholar
• Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am. J. Gastroenterol. 98(10), 2299–2305 (2003).
   PubMed Web of Science ®Google Scholar
• Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53(9), 1329–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int. J. Colorectal Dis. 23(10), 985–992 (2008).
   PubMed Web of Science ®Google Scholar
• Meucci G, D’Inca R, Maieron R et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig. Liver Dis. 42(3), 191–195 (2010).
   PubMedGoogle Scholar
• Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, Park JG. Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis. Colon Rectum 51(11), 1703–1709 (2008).
   PubMedGoogle Scholar
• Hirata I, Hoshimoto M, Saito O et al. Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J. Gastroenterol. 13(10), 1569–1574 (2007).
   PubMed Web of Science ®Google Scholar
• Davies RJ, Freeman A, Morris LS et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 359(9321), 1917–1919 (2002).
   PubMedGoogle Scholar
• Kim Y, Lee S, Park S et al. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann. Clin. Lab. Sci. 33(1), 32–38 (2003).
   PubMed Web of Science ®Google Scholar
• Mizuno M, Mizuno M, Iwagaki N et al. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer. Am. J. Gastroenterol. 98(11), 2550–2555 (2003).
   PubMedGoogle Scholar
• Pucci S, Bonanno E, Sesti F et al. Clusterin in stool: a new biomarker for colon cancer screening? Am. J. Gastroenterol. 104(11), 2807–2815 (2009).
   PubMed Web of Science ®Google Scholar
• Hardt PD, Mazurek S, Toepler M et al. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br. J. Cancer 91(5), 980–984 (2004).
   PubMed Web of Science ®Google Scholar
• Shastri YM, Naumann M, Oremek GM et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int. J. Cancer 119(11), 2651–2656 (2006).
   PubMed Web of Science ®Google Scholar
• Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J. Gastroenterol. 12(43), 7007–7011 (2006).
   PubMedGoogle Scholar
• Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br. J. Cancer 96(9), 1329–1334 (2007).
   PubMedGoogle Scholar
• Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br. J. Cancer 99(1), 133–135 (2008).
   PubMedGoogle Scholar
• Shastri YM, Loitsch S, Hoepffner N et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am. J. Gastroenterol. 103(6), 1496–1504 (2008).
   PubMedGoogle Scholar
• Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat. Rev. Cancer 5(3), 199–209 (2005).
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119(5), 1219–1227 (2000).
   PubMed Web of Science ®Google Scholar
• Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA. Cancer J. Clin. 58(3), 161–179 (2008).
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Sargent DJ, Loprinzi CL et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern. Med. 149(7), 441–450, W481 (2008).
   PubMed Web of Science ®Google Scholar
• Ahlquist DA, Zou H, Domanico M et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142(2), 248–256, quiz e225–e246 (2012).
   PubMed Web of Science ®Google Scholar
• Klaassen CH, Jeunink MA, Prinsen CF et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin. Chem. 49(7), 1185–1187 (2003).
   PubMedGoogle Scholar
• Onouchi S, Matsushita H, Moriya Y et al. New method for colorectal cancer diagnosis based on SSCP analysis of DNA from exfoliated colonocytes in naturally evacuated feces. Anticancer Res. 28(1A), 145–150 (2008).
   PubMed Web of Science ®Google Scholar
• Zou H, Taylor WR, Harrington JJ et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136(2), 459–470 (2009).
   PubMed Web of Science ®Google Scholar
• Li M, Chen WD, Papadopoulos N et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27(9), 858–863 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang X, Ma Q, Zhou Z, Fang J. Rapid detection of low-abundance K-ras mutation in stools of colorectal cancer patients using chip-based temperature gradient capillary electrophoresis. Lab. Invest. 91(5), 788–798 (2011).
   PubMed Web of Science ®Google Scholar
• Li BS, Wang XY, Xu AG et al. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms. Clin. Colorectal Cancer 11(4), 280–290 (2012).
   PubMed Web of Science ®Google Scholar
• Deng L, Qi Z, Zou B et al. Digital detection of multiple minority mutants in stool DNA for noninvasive colorectal cancer diagnosis. Anal. Chem. 84(13), 5645–5652 (2012).
   PubMedGoogle Scholar
• Oberwalder M, Zitt M, Wontner C et al. SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int. J. Colorectal Dis. 23(1), 15–19 (2008).
   PubMed Web of Science ®Google Scholar
• Wang DR, Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J. Gastroenterol. 14(4), 524–531 (2008).
   PubMed Web of Science ®Google Scholar
• Nagasaka T, Tanaka N, Cullings HM et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J. Natl Cancer Inst. 101(18), 1244–1258 (2009).
   PubMedGoogle Scholar
• Kalimutho M, Del Vecchio Blanco G, Cretella M et al. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. Int. J. Colorectal Dis. 26(5), 583–592 (2011).
   PubMedGoogle Scholar
• Itzkowitz S, Brand R, Jandorf L et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 103(11), 2862–2870 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang S, Xie Y et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China. Cancer Epidemiol. 36(1), 73–77 (2012).
   PubMedGoogle Scholar
• Glockner SC, Dhir M, Yi JM et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res. 69(11), 4691–4699 (2009).
   PubMed Web of Science ®Google Scholar
• Ausch C, Kim YH, Tsuchiya KD et al. Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA. Clin. Chem. 55(8), 1559–1563 (2009).
   PubMed Web of Science ®Google Scholar
• Hellebrekers DM, Lentjes MH, van den Bosch SM et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin. Cancer Res. 15(12), 3990–3997 (2009).
   PubMed Web of Science ®Google Scholar
• Kim MS, Louwagie J, Carvalho B et al. Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS ONE 4(8), e6555 (2009).
   PubMed Web of Science ®Google Scholar
• Mayor R, Casadome L, Azuara D et al. Long-range epigenetic silencing at 2q14.2 affects most human colorectal cancers and may have application as a non-invasive biomarker of disease. Br. J. Cancer 100(10), 1534–1539 (2009).
   PubMedGoogle Scholar
• Melotte V, Lentjes MH, van den Bosch SM et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl Cancer Inst. 101(13), 916–927 (2009).
   PubMed Web of Science ®Google Scholar
• Bosch LJ, Oort FA, Neerincx M et al. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT. Cancer Prev. Res. 5(3), 464–472 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang H, Song YC, Dang CX. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int. J. Med. Sci. 10(3), 230–234 (2013).
   PubMed Web of Science ®Google Scholar
• Baek YH, Chang E, Kim YJ, Kim BK, Sohn JH, Park DI. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis. Colon Rectum 52(8), 1452–1459, discussion 1459–1463 (2009).
   PubMed Web of Science ®Google Scholar
• Azuara D, Rodriguez-Moranta F, de Oca J et al. Novel methylation panel for the early detection of colorectal tumors in stool DNA. Clin. Colorectal Cancer 9(3), 168–176 (2010).
   PubMed Web of Science ®Google Scholar
• Elliott GO, Johnson IT, Scarll J et al. Quantitative profiling of CpG island methylation in human stool for colorectal cancer detection. Int. J. Colorectal Dis. 28(1), 35–42 (2013).
   PubMedGoogle Scholar
• Kisiel JB, Yab TC, Nazer Hussain FT et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 37(5), 546–554 (2013).
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340(8827), 1053–1058 (1992).
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Hanbury D, Smith J, Tarin D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 308(6929), 619–624 (1994).
   PubMedGoogle Scholar
• Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127(2), 422–427 (2004).
   PubMed Web of Science ®Google Scholar
• Takai T, Kanaoka S, Yoshida K et al. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 18(6), 1888–1893 (2009).
   PubMed Web of Science ®Google Scholar
• Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A, Kanaoka S. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br. J. Cancer 102(5), 916–921 (2010).
   PubMedGoogle Scholar
• Koga Y, Yasunaga M, Moriya Y et al. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci. 99(10), 1977–1983 (2008).
   PubMedGoogle Scholar
• Miyamoto C, Miyamoto N, Yamamoto H, Imai K, Shinomura Y. Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening. Oncol. Lett. 2(1), 95–100 (2011).
   PubMedGoogle Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259–269 (2006).
   PubMed Web of Science ®Google Scholar
• Koga Y, Yasunaga M, Moriya Y et al. Exosome can prevent RNase from degrading microRNA in feces. J. Gastrointest Oncol. 2(4), 215–222 (2011).
   PubMedGoogle Scholar
• Link A, Balaguer F, Shen Y et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 19(7), 1766–1774 (2010).
   PubMed Web of Science ®Google Scholar
• Koga Y, Yasunaga M, Takahashi A et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev. Res. 3(11), 1435–1442 (2010).
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Del Vecchio Blanco G, Di Cecilia S et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J. Gastroenterol. 46(12), 1391–1402 (2011).
   PubMed Web of Science ®Google Scholar
• Murata S, Koga Y, Moriya Y et al. Application of miRNA expression analysis on exfoliated colonocytes for colorectal cancer diagnosis. Gastrointestin. Cancer Targets Ther. 2, 11–18 (2012).
   Google Scholar
• Wu CW, Ng SS, Dong YJ et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61(5), 739–745 (2012).
   PubMed Web of Science ®Google Scholar
• Li R, Liu J, Xue H, Huang G. Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis. Int. J. Cancer 131(8), 1837–1845 (2012).
   PubMedGoogle Scholar
• Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J. Gastroenterol. 18(30), 4004–4011 (2012).
   PubMed Web of Science ®Google Scholar
• Leung WK, To KF, Man EP et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am. J. Gastroenterol. 102(5), 1070–1076 (2007).
   PubMed Web of Science ®Google Scholar
• Calistri D, Rengucci C, Casadei Gardini A et al. Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals. Cancer Epidemiol. Biomarkers Prev. 19(10), 2647–2654 (2010).
   PubMedGoogle Scholar